Biología molecular del cáncer
Hospital Universitario de Valme
Sevilla, EspañaPublicaciones en colaboración con investigadores/as de Hospital Universitario de Valme (7)
2024
-
Goodbye Hartmann trial: a prospective, international, multicenter, observational study on the current use of a surgical procedure developed a century ago
World Journal of Emergency Surgery, Vol. 19, Núm. 1
2023
-
Procalcitonin and C-reactive protein to rule out early bacterial coinfection in COVID-19 critically ill patients
Intensive Care Medicine, Vol. 49, Núm. 8, pp. 934-945
2022
-
Early short course of neuromuscular blocking agents in patients with COVID-19 ARDS: a propensity score analysis
Critical Care, Vol. 26, Núm. 1
2015
-
Role of circulating tumor cells as prognostic marker in resected stage III colorectal cancer
Annals of Oncology, Vol. 26, Núm. 3, pp. 535-541
2012
-
First-Line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study
Onkologie, Vol. 6, Núm. 2, pp. 96-103
-
First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: The phase III MACRO TTD study
Oncologist, Vol. 17, Núm. 1, pp. 15-25
2010
-
Consensus document on the use of biosimilar granulocyte-colony stimulating factor for the correction of neutropenia associated in cancer patients
Farmacia Hospitalaria, Vol. 34, Núm. SUPPL. 1, pp. 45-50